Review



elisa cpass sars-cov-2 nabs detection kit  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation elisa cpass sars-cov-2 nabs detection kit
    Elisa Cpass Sars Cov 2 Nabs Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+cpass+sars-cov-2+nabs+detection+kit/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc09393790-41-11-6
    Average 90 stars, based on 1 article reviews
    elisa cpass sars-cov-2 nabs detection kit - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
    Article Snippet: Avivi et al. ( ) , Roche Elecsys anti-SARS-CoV-2 immunoassay to detect IgG against Spike protein (receptor binding domain) with seropositivity cutoff of ≥ 0.8 U/mL , MM=133/181 (78%); HC=63/64 (98%) P=0.00013; active MM=121/159 (76%); all patients with SMM had a serological response. , Median active MM=91 U/mL (0–4875); SMM 822 U/mL (5-2878); HC=992 U/mL (0.4-5,000) , For MM=any AEs 53%, pain injection site 44%, fatigue 15%, muscle pain 14%, headache 14%, fever 6%, dizziness 4%, rash 2%, chills 2%, lymphadenopathy 1%; for HC=any AEs 55%, pain injection site 43%, fatigue 19%, muscle pain 6%, headache 8%, fever 4%, arthralgia 2% , Univariate analysis of active (comparing responder vs. non)=older age (above 65), high risk cytogenetics, lower level of level of polyclonal globulins, lower lymphocyte count, advanced treatment line (second or third line), greater number of new drugs the patient was exposed to before vaccination and depth of response to anti-myeloma therapy at vaccination time were associated with a lower response rate; Daratumumab-containing regimens trended towards a lower response rate; Multivariate analysis revealed older age (P=0·009), exposure to 4 new antimyeloma drugs (P=0·02) and hypogammaglobulinemia (P=0·002) were associated with lower response rates.. .. Gavriatopoulou et al. ( ) , GenScript ELISA cPass SARS-CoV-2 NAbs detection kit to detect NAbs with seropositivity cutoff of ≥ 30% , After the first dose: WM 34% (36/106) vs. HC 65% (138/212) with P<.001; After the second dose: WM 60.8% (45/74) vs. HC 92.5% (196/212) with P<.001 , After the first dose: WM median Nab inhibition titer 20.5% (IQR 10-37%) vs. HC 39.8% (IQR 21.9-53.4%) with P<.001. After the second dose: WM 36% (IQR 18-78%) vs. HC 92% (IQR 70-96%) with P<.001 , There were no differences between mild reactions (37% after the first dose vs. 38% after the second dose). Thirteen percent (after first dose) and 24% (after second dose) of patients developed systemic adverse reactions such as fatigue, fever, lymphadenopathy, muscle pain, arthralgia, headache. , BNT162b2 produced higher NAb compared to AZD1222 (median NAb 52% vs. 21.8% with P=.02). The asymptomatic subgroups had a higher median NAbs titer (52.9% vs. 44.3% for the symptomatic). Symptomatic patients who received Rituximab-based or Bruton tyrosine kinase as therapy showed suboptimal antibody response after vaccination.. .. Stampfer et al. ( ) , Sino biological ELISA to detect IgG against Spike protein with seropositivity cutoff of ≥ 250 IU/mL , Using the 250 IU/mL cutoff, 45% of the MM patients responded, 22% partially (above 50 IU/mL), and 33% did not responded; all 7 patients with smoldering MM responded to vaccination; 2/31 HC had partial response and 29/21 fully responded , Active MM median IgG spike antibody 173.7 IU/mL (range 0.1 - 8215.9 IU/mL); Smoldering MM median 555.8 IU/mL (range 283.1 - 3162.9 IU/mL); HC median 893.6 IU/mL (range 116.7 - 6006.4 IU/mL) , N/A , Younger patients (<68 years) developed higher anti-spike IgG levels. Neither sex nor race were correlated with vaccine response. Patients with low lymphocyte counts had inferior responses. Patients who received steroids as treatment had reduced antibody levels. More advanced disease and worse disease status were indicative of a poorer response to mRNA vaccination..

    Inhibition:

    Article Title: Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
    Article Snippet: Avivi et al. ( ) , Roche Elecsys anti-SARS-CoV-2 immunoassay to detect IgG against Spike protein (receptor binding domain) with seropositivity cutoff of ≥ 0.8 U/mL , MM=133/181 (78%); HC=63/64 (98%) P=0.00013; active MM=121/159 (76%); all patients with SMM had a serological response. , Median active MM=91 U/mL (0–4875); SMM 822 U/mL (5-2878); HC=992 U/mL (0.4-5,000) , For MM=any AEs 53%, pain injection site 44%, fatigue 15%, muscle pain 14%, headache 14%, fever 6%, dizziness 4%, rash 2%, chills 2%, lymphadenopathy 1%; for HC=any AEs 55%, pain injection site 43%, fatigue 19%, muscle pain 6%, headache 8%, fever 4%, arthralgia 2% , Univariate analysis of active (comparing responder vs. non)=older age (above 65), high risk cytogenetics, lower level of level of polyclonal globulins, lower lymphocyte count, advanced treatment line (second or third line), greater number of new drugs the patient was exposed to before vaccination and depth of response to anti-myeloma therapy at vaccination time were associated with a lower response rate; Daratumumab-containing regimens trended towards a lower response rate; Multivariate analysis revealed older age (P=0·009), exposure to 4 new antimyeloma drugs (P=0·02) and hypogammaglobulinemia (P=0·002) were associated with lower response rates.. .. Gavriatopoulou et al. ( ) , GenScript ELISA cPass SARS-CoV-2 NAbs detection kit to detect NAbs with seropositivity cutoff of ≥ 30% , After the first dose: WM 34% (36/106) vs. HC 65% (138/212) with P<.001; After the second dose: WM 60.8% (45/74) vs. HC 92.5% (196/212) with P<.001 , After the first dose: WM median Nab inhibition titer 20.5% (IQR 10-37%) vs. HC 39.8% (IQR 21.9-53.4%) with P<.001. After the second dose: WM 36% (IQR 18-78%) vs. HC 92% (IQR 70-96%) with P<.001 , There were no differences between mild reactions (37% after the first dose vs. 38% after the second dose). Thirteen percent (after first dose) and 24% (after second dose) of patients developed systemic adverse reactions such as fatigue, fever, lymphadenopathy, muscle pain, arthralgia, headache. , BNT162b2 produced higher NAb compared to AZD1222 (median NAb 52% vs. 21.8% with P=.02). The asymptomatic subgroups had a higher median NAbs titer (52.9% vs. 44.3% for the symptomatic). Symptomatic patients who received Rituximab-based or Bruton tyrosine kinase as therapy showed suboptimal antibody response after vaccination.. .. Stampfer et al. ( ) , Sino biological ELISA to detect IgG against Spike protein with seropositivity cutoff of ≥ 250 IU/mL , Using the 250 IU/mL cutoff, 45% of the MM patients responded, 22% partially (above 50 IU/mL), and 33% did not responded; all 7 patients with smoldering MM responded to vaccination; 2/31 HC had partial response and 29/21 fully responded , Active MM median IgG spike antibody 173.7 IU/mL (range 0.1 - 8215.9 IU/mL); Smoldering MM median 555.8 IU/mL (range 283.1 - 3162.9 IU/mL); HC median 893.6 IU/mL (range 116.7 - 6006.4 IU/mL) , N/A , Younger patients (<68 years) developed higher anti-spike IgG levels. Neither sex nor race were correlated with vaccine response. Patients with low lymphocyte counts had inferior responses. Patients who received steroids as treatment had reduced antibody levels. More advanced disease and worse disease status were indicative of a poorer response to mRNA vaccination..

    Produced:

    Article Title: Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
    Article Snippet: Avivi et al. ( ) , Roche Elecsys anti-SARS-CoV-2 immunoassay to detect IgG against Spike protein (receptor binding domain) with seropositivity cutoff of ≥ 0.8 U/mL , MM=133/181 (78%); HC=63/64 (98%) P=0.00013; active MM=121/159 (76%); all patients with SMM had a serological response. , Median active MM=91 U/mL (0–4875); SMM 822 U/mL (5-2878); HC=992 U/mL (0.4-5,000) , For MM=any AEs 53%, pain injection site 44%, fatigue 15%, muscle pain 14%, headache 14%, fever 6%, dizziness 4%, rash 2%, chills 2%, lymphadenopathy 1%; for HC=any AEs 55%, pain injection site 43%, fatigue 19%, muscle pain 6%, headache 8%, fever 4%, arthralgia 2% , Univariate analysis of active (comparing responder vs. non)=older age (above 65), high risk cytogenetics, lower level of level of polyclonal globulins, lower lymphocyte count, advanced treatment line (second or third line), greater number of new drugs the patient was exposed to before vaccination and depth of response to anti-myeloma therapy at vaccination time were associated with a lower response rate; Daratumumab-containing regimens trended towards a lower response rate; Multivariate analysis revealed older age (P=0·009), exposure to 4 new antimyeloma drugs (P=0·02) and hypogammaglobulinemia (P=0·002) were associated with lower response rates.. .. Gavriatopoulou et al. ( ) , GenScript ELISA cPass SARS-CoV-2 NAbs detection kit to detect NAbs with seropositivity cutoff of ≥ 30% , After the first dose: WM 34% (36/106) vs. HC 65% (138/212) with P<.001; After the second dose: WM 60.8% (45/74) vs. HC 92.5% (196/212) with P<.001 , After the first dose: WM median Nab inhibition titer 20.5% (IQR 10-37%) vs. HC 39.8% (IQR 21.9-53.4%) with P<.001. After the second dose: WM 36% (IQR 18-78%) vs. HC 92% (IQR 70-96%) with P<.001 , There were no differences between mild reactions (37% after the first dose vs. 38% after the second dose). Thirteen percent (after first dose) and 24% (after second dose) of patients developed systemic adverse reactions such as fatigue, fever, lymphadenopathy, muscle pain, arthralgia, headache. , BNT162b2 produced higher NAb compared to AZD1222 (median NAb 52% vs. 21.8% with P=.02). The asymptomatic subgroups had a higher median NAbs titer (52.9% vs. 44.3% for the symptomatic). Symptomatic patients who received Rituximab-based or Bruton tyrosine kinase as therapy showed suboptimal antibody response after vaccination.. .. Stampfer et al. ( ) , Sino biological ELISA to detect IgG against Spike protein with seropositivity cutoff of ≥ 250 IU/mL , Using the 250 IU/mL cutoff, 45% of the MM patients responded, 22% partially (above 50 IU/mL), and 33% did not responded; all 7 patients with smoldering MM responded to vaccination; 2/31 HC had partial response and 29/21 fully responded , Active MM median IgG spike antibody 173.7 IU/mL (range 0.1 - 8215.9 IU/mL); Smoldering MM median 555.8 IU/mL (range 283.1 - 3162.9 IU/mL); HC median 893.6 IU/mL (range 116.7 - 6006.4 IU/mL) , N/A , Younger patients (<68 years) developed higher anti-spike IgG levels. Neither sex nor race were correlated with vaccine response. Patients with low lymphocyte counts had inferior responses. Patients who received steroids as treatment had reduced antibody levels. More advanced disease and worse disease status were indicative of a poorer response to mRNA vaccination..



    Similar Products

    elisa cpass sars-cov-2 nabs detection kit  (GenScript corporation)
    90
    GenScript corporation elisa cpass sars-cov-2 nabs detection kit
    Elisa Cpass Sars Cov 2 Nabs Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+cpass+sars-cov-2+nabs+detection+kit/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc09393790-41-11-6
    Average 90 stars, based on 1 article reviews
    elisa cpass sars-cov-2 nabs detection kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    elisa, cpass tm sars-cov-2 nabs detection kit  (GenScript corporation)
    90
    GenScript corporation elisa, cpass tm sars-cov-2 nabs detection kit
    Elisa, Cpass Tm Sars Cov 2 Nabs Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+cpass+sars-cov-2+nabs+detection+kit/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc08987172-63-6-13
    Average 90 stars, based on 1 article reviews
    elisa, cpass tm sars-cov-2 nabs detection kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results